On key measures Keynote-D77 shows subcutaneous delivery to be the equal of IV.

In first-line SCLC BNT327 looks better than Tecentriq, but data will need to be replicated outside China.

Ikena, Senti and others look to clinical presentations at AACR.

The company is abandoning ovarian and bladder, but still sees a path in endometrial cancer.

Skyscraper-01 stars at AACR's upcoming clinical trial plenary.

The anti-PD-1 x CTLA-4 bispecific impresses in cervical cancer, but US plans are on ice.

The Artistry-7 Keytruda combo trial fails, spurring discontinuation in ovarian cancer.

The company is stepping back in second-line breast cancer.